Loading…

Use of Multifactorial Treatments to Address the Challenge of Translating Experimental Myocardial Infarct Reduction Strategies

Myocardial tissue damage that occurs during an ischemic event leads to a spiraling deterioration of cardiac muscle structural and functional integrity. Reperfusion is the only known efficacious strategy and is the most commonly used treatment to reduce injury and prevent remodeling. However, timing...

Full description

Saved in:
Bibliographic Details
Published in:International journal of molecular sciences 2019-03, Vol.20 (6), p.1449
Main Authors: Horton, Julie L, Virag, Jitka
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c478t-41ab1f4bb2b05fcb53cbf93ebd429df3d06469a4dcf649484557712f5fa779783
cites cdi_FETCH-LOGICAL-c478t-41ab1f4bb2b05fcb53cbf93ebd429df3d06469a4dcf649484557712f5fa779783
container_end_page
container_issue 6
container_start_page 1449
container_title International journal of molecular sciences
container_volume 20
creator Horton, Julie L
Virag, Jitka
description Myocardial tissue damage that occurs during an ischemic event leads to a spiraling deterioration of cardiac muscle structural and functional integrity. Reperfusion is the only known efficacious strategy and is the most commonly used treatment to reduce injury and prevent remodeling. However, timing is critical, and the procedure is not always feasible for a variety of reasons. The complex molecular basis for cardioprotection has been studied for decades but formulation of a viable therapeutic that can significantly attenuate myocardial injury remains elusive. In this review, we address barriers to the development of a fruitful approach that will substantially improve the prognosis of those suffering from this widespread and largely unmitigated disease. Furthermore, we proffer that ephrinA1, a candidate molecule that satisfies many of the important criteria discussed, possesses robust potential to overcome these hurdles and thus offers protection that surpasses the limitations currently observed.
doi_str_mv 10.3390/ijms20061449
format article
fullrecord <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_5ef43e8150a0437abf7123a36513f94b</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_5ef43e8150a0437abf7123a36513f94b</doaj_id><sourcerecordid>2197887905</sourcerecordid><originalsourceid>FETCH-LOGICAL-c478t-41ab1f4bb2b05fcb53cbf93ebd429df3d06469a4dcf649484557712f5fa779783</originalsourceid><addsrcrecordid>eNpdkktvEzEURkcIREthxxqNxIYFAb9mPN4gVVELkVohQbq2rl-JI2ccbA-iC_57naZUKSu_zj36rnWb5i1GnygV6LPfbDNBqMeMiWfNKWaEzOqRPz_anzSvct4gRCjpxMvmhCKBBOX9afP3Jts2uvZ6CsU70CUmD6FdJgtla8eS2xLbc2OSzXW7tu18DSHYcXVftUww5gDFj6v24s_OJr-vqfXXt1FDMnvVYnSQdGl_WDPp4uPY_iwJil15m183LxyEbN88rGfNzeXFcv5tdvX962J-fjXTjA9lxjAo7JhSRKHOadVRrZygVhlGhHHUoJ71ApjRrmeCDazrOMfEdQ44F3ygZ83i4DURNnJXY0K6lRG8vL-IaSUhFa-DlZ11jNoBdwgQoxyUqyYKtO8wdYKp6vpycO0mtbVG14YThCfSpy-jX8tV_C17xjGj-zAfHgQp_ppsLnLrs7YhwGjjlCXBNfLABeoq-v4_dBOnNNavkoTSCg696Cv18UDpFHNO1j2GwUjuZ0Qez0jF3x038Aj_Gwp6B8Jzud4</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2332198696</pqid></control><display><type>article</type><title>Use of Multifactorial Treatments to Address the Challenge of Translating Experimental Myocardial Infarct Reduction Strategies</title><source>Open Access: PubMed Central</source><source>ProQuest - Publicly Available Content Database</source><creator>Horton, Julie L ; Virag, Jitka</creator><creatorcontrib>Horton, Julie L ; Virag, Jitka</creatorcontrib><description>Myocardial tissue damage that occurs during an ischemic event leads to a spiraling deterioration of cardiac muscle structural and functional integrity. Reperfusion is the only known efficacious strategy and is the most commonly used treatment to reduce injury and prevent remodeling. However, timing is critical, and the procedure is not always feasible for a variety of reasons. The complex molecular basis for cardioprotection has been studied for decades but formulation of a viable therapeutic that can significantly attenuate myocardial injury remains elusive. In this review, we address barriers to the development of a fruitful approach that will substantially improve the prognosis of those suffering from this widespread and largely unmitigated disease. Furthermore, we proffer that ephrinA1, a candidate molecule that satisfies many of the important criteria discussed, possesses robust potential to overcome these hurdles and thus offers protection that surpasses the limitations currently observed.</description><identifier>ISSN: 1422-0067</identifier><identifier>ISSN: 1661-6596</identifier><identifier>EISSN: 1422-0067</identifier><identifier>DOI: 10.3390/ijms20061449</identifier><identifier>PMID: 30909376</identifier><language>eng</language><publisher>Switzerland: MDPI AG</publisher><subject>Animals ; cardioprotection ; Cardiotonic Agents ; Combined Modality Therapy ; Diabetes ; Disease Management ; Economic impact ; Ephrin-A1 - genetics ; Ephrin-A1 - metabolism ; Ephrin-A1 - therapeutic use ; Ephrin-A1 - ultrastructure ; ephrinA1 ; Heart attacks ; Heart failure ; Humans ; Immunoglobulin Fc Fragments - therapeutic use ; Immunoglobulin Fc Fragments - ultrastructure ; Ischemia ; Ligands ; Mortality ; Myocardial infarction ; Myocardial Infarction - diagnosis ; Myocardial Infarction - etiology ; Myocardial Infarction - metabolism ; Myocardial Infarction - therapy ; Oxidation ; Patients ; Recombinant Fusion Proteins - therapeutic use ; Recombinant Fusion Proteins - ultrastructure ; Reperfusion ; Review ; Scars ; Socioeconomic factors ; therapeutic strategies ; Translational Research, Biomedical ; Treatment Outcome</subject><ispartof>International journal of molecular sciences, 2019-03, Vol.20 (6), p.1449</ispartof><rights>2019. This work is licensed under https://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2019 by the authors. 2019</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c478t-41ab1f4bb2b05fcb53cbf93ebd429df3d06469a4dcf649484557712f5fa779783</citedby><cites>FETCH-LOGICAL-c478t-41ab1f4bb2b05fcb53cbf93ebd429df3d06469a4dcf649484557712f5fa779783</cites><orcidid>0000-0003-3321-9861</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2332198696/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2332198696?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,25753,27924,27925,37012,37013,44590,53791,53793,74998</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30909376$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Horton, Julie L</creatorcontrib><creatorcontrib>Virag, Jitka</creatorcontrib><title>Use of Multifactorial Treatments to Address the Challenge of Translating Experimental Myocardial Infarct Reduction Strategies</title><title>International journal of molecular sciences</title><addtitle>Int J Mol Sci</addtitle><description>Myocardial tissue damage that occurs during an ischemic event leads to a spiraling deterioration of cardiac muscle structural and functional integrity. Reperfusion is the only known efficacious strategy and is the most commonly used treatment to reduce injury and prevent remodeling. However, timing is critical, and the procedure is not always feasible for a variety of reasons. The complex molecular basis for cardioprotection has been studied for decades but formulation of a viable therapeutic that can significantly attenuate myocardial injury remains elusive. In this review, we address barriers to the development of a fruitful approach that will substantially improve the prognosis of those suffering from this widespread and largely unmitigated disease. Furthermore, we proffer that ephrinA1, a candidate molecule that satisfies many of the important criteria discussed, possesses robust potential to overcome these hurdles and thus offers protection that surpasses the limitations currently observed.</description><subject>Animals</subject><subject>cardioprotection</subject><subject>Cardiotonic Agents</subject><subject>Combined Modality Therapy</subject><subject>Diabetes</subject><subject>Disease Management</subject><subject>Economic impact</subject><subject>Ephrin-A1 - genetics</subject><subject>Ephrin-A1 - metabolism</subject><subject>Ephrin-A1 - therapeutic use</subject><subject>Ephrin-A1 - ultrastructure</subject><subject>ephrinA1</subject><subject>Heart attacks</subject><subject>Heart failure</subject><subject>Humans</subject><subject>Immunoglobulin Fc Fragments - therapeutic use</subject><subject>Immunoglobulin Fc Fragments - ultrastructure</subject><subject>Ischemia</subject><subject>Ligands</subject><subject>Mortality</subject><subject>Myocardial infarction</subject><subject>Myocardial Infarction - diagnosis</subject><subject>Myocardial Infarction - etiology</subject><subject>Myocardial Infarction - metabolism</subject><subject>Myocardial Infarction - therapy</subject><subject>Oxidation</subject><subject>Patients</subject><subject>Recombinant Fusion Proteins - therapeutic use</subject><subject>Recombinant Fusion Proteins - ultrastructure</subject><subject>Reperfusion</subject><subject>Review</subject><subject>Scars</subject><subject>Socioeconomic factors</subject><subject>therapeutic strategies</subject><subject>Translational Research, Biomedical</subject><subject>Treatment Outcome</subject><issn>1422-0067</issn><issn>1661-6596</issn><issn>1422-0067</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNpdkktvEzEURkcIREthxxqNxIYFAb9mPN4gVVELkVohQbq2rl-JI2ccbA-iC_57naZUKSu_zj36rnWb5i1GnygV6LPfbDNBqMeMiWfNKWaEzOqRPz_anzSvct4gRCjpxMvmhCKBBOX9afP3Jts2uvZ6CsU70CUmD6FdJgtla8eS2xLbc2OSzXW7tu18DSHYcXVftUww5gDFj6v24s_OJr-vqfXXt1FDMnvVYnSQdGl_WDPp4uPY_iwJil15m183LxyEbN88rGfNzeXFcv5tdvX962J-fjXTjA9lxjAo7JhSRKHOadVRrZygVhlGhHHUoJ71ApjRrmeCDazrOMfEdQ44F3ygZ83i4DURNnJXY0K6lRG8vL-IaSUhFa-DlZ11jNoBdwgQoxyUqyYKtO8wdYKp6vpycO0mtbVG14YThCfSpy-jX8tV_C17xjGj-zAfHgQp_ppsLnLrs7YhwGjjlCXBNfLABeoq-v4_dBOnNNavkoTSCg696Cv18UDpFHNO1j2GwUjuZ0Qez0jF3x038Aj_Gwp6B8Jzud4</recordid><startdate>20190322</startdate><enddate>20190322</enddate><creator>Horton, Julie L</creator><creator>Virag, Jitka</creator><general>MDPI AG</general><general>MDPI</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0003-3321-9861</orcidid></search><sort><creationdate>20190322</creationdate><title>Use of Multifactorial Treatments to Address the Challenge of Translating Experimental Myocardial Infarct Reduction Strategies</title><author>Horton, Julie L ; Virag, Jitka</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c478t-41ab1f4bb2b05fcb53cbf93ebd429df3d06469a4dcf649484557712f5fa779783</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Animals</topic><topic>cardioprotection</topic><topic>Cardiotonic Agents</topic><topic>Combined Modality Therapy</topic><topic>Diabetes</topic><topic>Disease Management</topic><topic>Economic impact</topic><topic>Ephrin-A1 - genetics</topic><topic>Ephrin-A1 - metabolism</topic><topic>Ephrin-A1 - therapeutic use</topic><topic>Ephrin-A1 - ultrastructure</topic><topic>ephrinA1</topic><topic>Heart attacks</topic><topic>Heart failure</topic><topic>Humans</topic><topic>Immunoglobulin Fc Fragments - therapeutic use</topic><topic>Immunoglobulin Fc Fragments - ultrastructure</topic><topic>Ischemia</topic><topic>Ligands</topic><topic>Mortality</topic><topic>Myocardial infarction</topic><topic>Myocardial Infarction - diagnosis</topic><topic>Myocardial Infarction - etiology</topic><topic>Myocardial Infarction - metabolism</topic><topic>Myocardial Infarction - therapy</topic><topic>Oxidation</topic><topic>Patients</topic><topic>Recombinant Fusion Proteins - therapeutic use</topic><topic>Recombinant Fusion Proteins - ultrastructure</topic><topic>Reperfusion</topic><topic>Review</topic><topic>Scars</topic><topic>Socioeconomic factors</topic><topic>therapeutic strategies</topic><topic>Translational Research, Biomedical</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Horton, Julie L</creatorcontrib><creatorcontrib>Virag, Jitka</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>ProQuest_Research Library</collection><collection>Research Library (Corporate)</collection><collection>ProQuest - Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>International journal of molecular sciences</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Horton, Julie L</au><au>Virag, Jitka</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Use of Multifactorial Treatments to Address the Challenge of Translating Experimental Myocardial Infarct Reduction Strategies</atitle><jtitle>International journal of molecular sciences</jtitle><addtitle>Int J Mol Sci</addtitle><date>2019-03-22</date><risdate>2019</risdate><volume>20</volume><issue>6</issue><spage>1449</spage><pages>1449-</pages><issn>1422-0067</issn><issn>1661-6596</issn><eissn>1422-0067</eissn><abstract>Myocardial tissue damage that occurs during an ischemic event leads to a spiraling deterioration of cardiac muscle structural and functional integrity. Reperfusion is the only known efficacious strategy and is the most commonly used treatment to reduce injury and prevent remodeling. However, timing is critical, and the procedure is not always feasible for a variety of reasons. The complex molecular basis for cardioprotection has been studied for decades but formulation of a viable therapeutic that can significantly attenuate myocardial injury remains elusive. In this review, we address barriers to the development of a fruitful approach that will substantially improve the prognosis of those suffering from this widespread and largely unmitigated disease. Furthermore, we proffer that ephrinA1, a candidate molecule that satisfies many of the important criteria discussed, possesses robust potential to overcome these hurdles and thus offers protection that surpasses the limitations currently observed.</abstract><cop>Switzerland</cop><pub>MDPI AG</pub><pmid>30909376</pmid><doi>10.3390/ijms20061449</doi><orcidid>https://orcid.org/0000-0003-3321-9861</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1422-0067
ispartof International journal of molecular sciences, 2019-03, Vol.20 (6), p.1449
issn 1422-0067
1661-6596
1422-0067
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_5ef43e8150a0437abf7123a36513f94b
source Open Access: PubMed Central; ProQuest - Publicly Available Content Database
subjects Animals
cardioprotection
Cardiotonic Agents
Combined Modality Therapy
Diabetes
Disease Management
Economic impact
Ephrin-A1 - genetics
Ephrin-A1 - metabolism
Ephrin-A1 - therapeutic use
Ephrin-A1 - ultrastructure
ephrinA1
Heart attacks
Heart failure
Humans
Immunoglobulin Fc Fragments - therapeutic use
Immunoglobulin Fc Fragments - ultrastructure
Ischemia
Ligands
Mortality
Myocardial infarction
Myocardial Infarction - diagnosis
Myocardial Infarction - etiology
Myocardial Infarction - metabolism
Myocardial Infarction - therapy
Oxidation
Patients
Recombinant Fusion Proteins - therapeutic use
Recombinant Fusion Proteins - ultrastructure
Reperfusion
Review
Scars
Socioeconomic factors
therapeutic strategies
Translational Research, Biomedical
Treatment Outcome
title Use of Multifactorial Treatments to Address the Challenge of Translating Experimental Myocardial Infarct Reduction Strategies
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T05%3A09%3A54IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Use%20of%20Multifactorial%20Treatments%20to%20Address%20the%20Challenge%20of%20Translating%20Experimental%20Myocardial%20Infarct%20Reduction%20Strategies&rft.jtitle=International%20journal%20of%20molecular%20sciences&rft.au=Horton,%20Julie%20L&rft.date=2019-03-22&rft.volume=20&rft.issue=6&rft.spage=1449&rft.pages=1449-&rft.issn=1422-0067&rft.eissn=1422-0067&rft_id=info:doi/10.3390/ijms20061449&rft_dat=%3Cproquest_doaj_%3E2197887905%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c478t-41ab1f4bb2b05fcb53cbf93ebd429df3d06469a4dcf649484557712f5fa779783%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2332198696&rft_id=info:pmid/30909376&rfr_iscdi=true